Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00334347
Other study ID # 2006-P-000671
Secondary ID
Status Completed
Phase Phase 4
First received June 5, 2006
Last updated December 3, 2007
Start date June 2006
Est. completion date September 2007

Study information

Verified date December 2007
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

To compare the time to response, response rates, remission rates, and side effects in Bipolar Disorder inpatients treated with Depakote ER or Depakote DR for acute mania or mixed mania.


Description:

There are several studies demonstrating the efficacy of divalproex in the acute treatment of mania and mixed mania. In fact, the American Psychiatric Associations Practice Guidelines for Bipolar Disorder recommends divalproex as a first-line treatment for acute mania and acute mixed mania; divalproex is the treatment of choice in the treatment of acute mixed mania. The Food and Drug Administration (FDA) approved divalproex for the acute treatment of mania in the 1990's. A new formulation, divalproex, Depakote ER, was recently FDA approved for the treatment of epilepsy and prophylaxis of migraine headaches. In a pooled data analysis of nine open-labeled trials involving 321 epilepsy and bipolar disorder patients, Smith et al. that Depakote ER was associated with superior tolerability including less frequent tremors, weight gain, and gastrointestinal complaints (all p<0.001) compared with Depakote DR. Depakote ER was preferred by subjects and it provided improved seizure control and a greater reduction in psychiatric symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

- Males and females between the ages 19-65 (inclusive).

- DSM-IV diagnosis of acute mania or acute mixed mania .

Exclusion Criteria:

- DSM-IV diagnoses of bipolar disorder, depressed type, bipolar disorder rapid cycling type, major depressive disorder with psychotic features, schizoaffective disorder, schizophrenia, substance use disorder (active use within the last 3 months), or organic mood disorder.

- History of a seizure disorder or an unstable physical disorder judged to significantly affect central nervous system function.

- Female subjects who are pregnant or of childbearing potential who are not using medically accepted means of contraception and female patients who are breastfeeding.

- Subjects who require antipsychotic medications because of severe psychosis and /or agitation.

- Subjects on antidepressants or mood stabilizers including lithium, oxcarbazepine, carbamazepine, and lamotrigine.

- Subjects who have failed previous trials with Depakote DR or Depakote ER.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Depakote ER
The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
Depakote DR
The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts General Hospital Abbott

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Young Mania Rating Scale (YMRS)will be used daily for the first week and then every three day to assess the severity of mania. study duration
Primary The Clinical Global Impression Scale (CGI) will be used daily for teh first week then every 3 days to assess overall functioning. study duration
Primary The Udvalg for Kliniske Undersogeiser (UKU) Side Effect Rating Scale will be administered at base line and weekly for the remainder of the study to determine the medication side effect profiles. study duration
Secondary The Montgomery-Asberg Depression Rating Scale will be performed daily for the first week and weekly thereafter to assess for any emergent symptoms of depression. study duration
Secondary The Brief Psychiatric Rating Scale (BPRS) will be performed daily for the first week and weekly thereafter to assess for any emergent symptoms of psychosis. study duration
Secondary The Drug Attitude Inventory (DAI-10)will measure subjects' attitudes towards medications at the screen and final visit. study duration
Secondary The Schizophrenia Quality of Life Scale (SQLS)will measure subjects' quality of life at the screen and final visit. study duration
See also
  Status Clinical Trial Phase
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT00534222 - Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect N/A
Completed NCT00140179 - Valnoctamide in Mania Phase 3
Completed NCT01237379 - Peroxisomal Defects and Familial Risk for Bipolar Disorder N/A
Completed NCT01315028 - Bipolar Intervention Study: Cognitive Interpersonal Therapy N/A
Completed NCT00254488 - Treatment of Bipolar Mania in Older Adults Phase 4
Completed NCT00560079 - Efficacy of Allopurinol and Dypiridamole in Acute Mania Phase 4
Completed NCT00518947 - Pharmacotherapy of Treatment-Resistant Mania Phase 3
Recruiting NCT05444907 - Deep Brain Stimulation-Induced Mania in Parkinson's Disease
Enrolling by invitation NCT02360267 - Pediatric Bipolar Registry
Completed NCT01092221 - Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode Phase 3
Completed NCT00521365 - Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder. Phase 4
Completed NCT01191918 - The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania Phase 4
Completed NCT01541605 - Methylphenidate for the Treatment of Acute Mania Phase 3
Completed NCT00893581 - Multimodal Neuroimaging of Treatment Effects in Adolescent Mania N/A
Completed NCT00208195 - Depakote ER Therapy for Mania Comorbid With Substance Abuse Phase 4
Completed NCT00181922 - Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder Phase 4
Completed NCT00181935 - Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder Phase 4
Active, not recruiting NCT05703711 - Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa N/A
Completed NCT00917501 - Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania Phase 2